AlTi Global’s Alnylam Pharmaceuticals ALNY Stock Holding History

AlTi Global’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-602	Closed	-$239K	–	439
2025 Q4	$239K	Buy	602 +26	+5%	+$11.5K	0.01%	420
2025 Q3	$263K	Buy	+576	New	+$235K	0.01%	387

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AlTi Global's ALNY Position: Q1 2026 in Review

AlTi Global sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 602 shares — an estimated $239K sold.

AlTi Global first reported a position in ALNY in Q3 2025 and held it in 2 quarters. The position peaked at $263K in Q3 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

AlTi Global reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
AlTi Global sold 602 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $239K.
AlTi Global first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 2 quarters.
AlTi Global's Alnylam Pharmaceuticals position peaked at $263K in Q3 2025.
789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on AlTi Global's 13F filing for Q1 2026, filed 7 May 2026.